BioAge Puts VC Muscle Behind Phase II Azelaprag Trials In Obesity

The company completed a $170m series D round and plans to start trials combining the drug with GLP-1 agonists like Eli Lilly’s Zepbound in mid-2024.

• Source: Shutterstock

Aging-focused startup BioAge Labs, Inc. is gaining a key partner in metabolic disease for the upcoming Phase II trial of azelaprag for improving body composition in patients on GLP-1/incretin therapy for obesity. The company announced on 13 February the closing of a large series D venture capital funding round, which it will direct toward development of azelaprag in combination with Eli Lilly and Company’s Zepbound (tirzepatide) and other incretins, and a partnership with Lilly’s Chorus organization.

The financing will be used to investigate BioAge drug’s ability to promote weight loss and improve body composition in combination...

More from Financing

More from Business